There are currently 117 active clinical trials seeking participants for Head and Neck Cancer research studies. The states with the highest number of trials for Head and Neck Cancer participants are California, Ohio, Pennsylvania and New York.
A Prospective Imaging Study of the Integrated TrueBeam-HyperSight CBCT System
NCT05975619
Recruiting
Cone beam computed tomography (CBCT) images are routinely used in radiation treatment delivery workflows to align patients with the treatment beam. Conventional CBCT image quality is sufficient for this task but not good enough for other radiotherapy-related tasks, such as contouring anatomical structures and calculating radiation dose distributions. HyperSight is a new CBCT imaging system manufactured by Varian Medical Systems. The purpose of this study is to evaluate the integration of the Hyp... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/05/2023
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Head and Neck Cancer, Thoracic Cancer, Abdominal Cancer, Pelvic Cancer
Register for Updates
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05864144
Recruiting
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Icahn School of Medicine at Mt. Sinai, New York, New York +4 locations
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer
Register for Updates
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT04915183
Recruiting
Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objective: To find out if atorvastatin reduces hearing loss in people treated with cisplatin and radiation. Eligibility: People ages 18 and older with squamous cell carcinoma of the head and neck who will undergo treatment with cisplatin-based chemotherapy and ra... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/13/2024
Locations: Winship Cancer Institute at Emory University, Atlanta, Georgia +3 locations
Conditions: Hearing Loss, Head and Neck Cancer
Register for Updates
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
NCT06056310
Recruiting
The purpose of this study is to evaluate the tolerability and safety of Xevinapant when added to weekly cisplatin-based concurrent chemoradiotherapy (CRT) in the treatment of participants with unresectable locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida +22 locations
Conditions: Head and Neck Cancer
Register for Updates
"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
NCT04373642
Recruiting
The purpose of this study is to test the safety of palliative "QUAD SHOT" radiotherapy combined with pembrolizumab and evaluate the effects of the combination treatment patients with recurrent cancer of head and neck.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Head and Neck Cancer
Register for Updates
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
NCT05973487
Recruiting
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after ly... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: HonorHealth Research and Innovation Institute, Scottsdale, Arizona +13 locations
Conditions: Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Register for Updates
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
NCT05576974
Recruiting
This is a non-randomized, open-label, single-center, safety and imaging feasibility study of Pegsitacianine, an intraoperative fluorescence imaging agent.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/08/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Head and Neck Cancer, Unknown Primary Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
NCT05108870
Recruiting
Doctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the study (induction) and if combining these medications can increase tumor shrinkage after therapy and reduce the amount of radiotherapy and chemotherapy that will later be needed. In addition, the study is looking at ways to reduce side effects overall using robotic surgery,... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
Register for Updates
Improving Care for Rural Patients With Solid Tumors
NCT04916990
Recruiting
This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment completion for solid tumors (ex: lung, head, neck, thyroid, cervical, breast, bladder, colon, and rectal cancers) in rural patients.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/08/2024
Locations: University of Colorado Hospital, Aurora, Colorado +10 locations
Conditions: Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Colon Cancer, Rectum Cancer
Register for Updates
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750
Recruiting
This Phase 1/2 study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 (INN: rezatapopt) alone (monotherapy) and in combination with pembrolizumab in participants with advanced solid tumors containing a TP53 Y220C mutation.
Gender:
All
Ages:
12 years and above
Trial Updated:
05/07/2024
Locations: University of California, San Diego, La Jolla, California +53 locations
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
Register for Updates
Perioperative Nutritional Optimization in Head and Neck Cancer Patients
NCT04449445
Recruiting
To determine whether nutritional optimization in head and neck cancer patients undergoing major surgery will decrease post-operative wound complications. The Investigators hypothesize that nutritional supplementation with Nestle Impact Advanced Recovery (AR) will decrease the rate of wound complications after surgery
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Head and Neck Cancer
Register for Updates
Study of ALE.C04 in Patients With Head and Neck Cancer
NCT06054477
Recruiting
The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and as monotherapy and to assess anti-tumor activity of ALE.C04 monotherapy and in combination with pembrolizumab in patients with Head and Neck Cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +14 locations
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates